Kinevant Sciences

Kinevant Sciences

  • Founded: 2018
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Pulmonary sarcoidosis
  • Drug types: LNG
  • Lead product: Namilumab
  • Product link:
  • Funding: not disclosed

job board

Short description:

Sarcoidosis Treatment

Drug notes:

Contact us to add description:

Long description:

Kinevant Sciences is developing new therapies for rare inflammatory and autoimmune diseases. Cytokines are small proteins that regulate the immune system and play a role in driving many inflammatory diseases. Many cytokines are already validated as targets for treating inflammatory diseases, and Kinevant is further expanding the potential. Kinevant’s lead candidate, namilumab, is a novel monoclonal antibody being developed for pulmonary sarcoidosis treatment. Namilumab targets a key pro-inflammatory cytokine involved in the disease, GM-CSF, and has been demonstrated to be well-tolerated in multiple clinical trials. Plans are in place to start Phase 2 trials in patients soon.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy